Lawrence Liberti

List of Publications by Year
in descending order

15	153	1307594 7	1199594 12
papers	citations	h-index	g-index

15	15	15	145
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Building Synergy between Regulatory and HTA Agencies beyond Processes and Proceduresâ€"Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions. Value in Health, 2018, 21, 707-714.	0.3	30
2	A Universal Framework for the Benefit-Risk Assessment of Medicines: Is This the Way Forward?. Therapeutic Innovation and Regulatory Science, 2015, 49, 17-25.	1.6	25
3	FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines. Frontiers in Pharmacology, 2017, 8, 161.	3.5	21
4	Accelerating access to new medicines: Current status of facilitated regulatory pathways used by emerging regulatory authorities. Journal of Public Health Policy, 2016, 37, 315-333.	2.0	17
5	A Baseline Analysis of Regulatory Review Timelines for ANVISA: 2013â€"2016. Therapeutic Innovation and Regulatory Science, 2020, 54, 1428-1435.	1.6	10
6	Characterizing Good Review Practices: A Survey Report Among Agencies of APEC Member Economies. Therapeutic Innovation and Regulatory Science, 2013, 47, 678-683.	1.6	8
7	Factors related to drug approvals: predictors of outcome?. Drug Discovery Today, 2017, 22, 937-946.	6.4	8
8	Standardizing the Benefit-Risk Assessment of New Medicines. Pharmaceutical Medicine, 2011, 25, 139-146.	1.9	7
9	Observations on Three Endpoint Properties and Their Relationship to Regulatory Outcomes of European Oncology Marketing Applications. Oncologist, 2015, 20, 683-691.	3.7	7
10	Improving access to quality medicines in East Africa: An independent perspective on theÂEast African CommunityÂMedicines Regulatory Harmonization initiative. PLoS Medicine, 2020, 17, e1003092.	8.4	6
11	A Proposed Framework for a Globally Applicable Pragmatic Approach to Using Facilitated Regulatory Pathways. Therapeutic Innovation and Regulatory Science, 2020, 54, 55-68.	1.6	5
12	The Qualitative Value of Facilitated Regulatory Pathways in Europe, USA, and Japan: Benefits, Barriers to Utilization, and Suggested Solutions. Pharmaceutical Medicine, 2021, 35, 113-122.	1.9	4
13	A Proposed Framework for a Globally Applicable Pragmatic Approach to Using Facilitated Regulatory Pathways. Therapeutic Innovation and Regulatory Science, 2018, , 216847901881397.	1.6	2
14	Transparency in European Medicines Agency and US Food and Drug Administration Decision Making: Is It Possible to Identify the Rationale for Divergences in Approved Indication From Public Assessment Reports?. Clinical Therapeutics, 2021, 43, 888-905.	2.5	2
15	An evaluation of the Caribbean regulatory system centralized assessment process for medicines submitted 2017â€"2018 using the OpERA methodology. Journal of Pharmaceutical Policy and Practice, 2020, 13, 56.	2.4	1